Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
Kaysia Ludford(The University of Texas MD Anderson Cancer Center), Michael J. Overman(The University of Texas MD Anderson Cancer Center), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Carlos Kamiya-Matsuoka(The University of Texas MD Anderson Cancer Center), Wai Chin Foo(The University of Texas MD Anderson Cancer Center), Benny Johnson(The University of Texas MD Anderson Cancer Center), Jane V. Thomas(The University of Texas MD Anderson Cancer Center), Arvind Dasari(The University of Texas MD Anderson Cancer Center), Xuan Yuan(Johns Hopkins University), Brandon G. Smaglo(The University of Texas MD Anderson Cancer Center), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Selvi Thirumurthi(The University of Texas MD Anderson Cancer Center), Won Jin Ho(Johns Hopkins University), Sarah M. Shin(Sidney Kimmel Comprehensive Cancer Center), Eduardo Vilar(The University of Texas MD Anderson Cancer Center), Matthew M. Tillman(The University of Texas MD Anderson Cancer Center), Dipen M. Maru(The University of Texas MD Anderson Cancer Center), M Murphy(The University of Texas MD Anderson Cancer Center), Michael S. Lee(Duke Medical Center), Wei Qiao(The University of Texas MD Anderson Cancer Center), Craig Messick(The University of Texas MD Anderson Cancer Center), Nicole D. Fleming(The University of Texas MD Anderson Cancer Center), Y. Nancy You(The University of Texas MD Anderson Cancer Center), Hongqui Yang(Sidney Kimmel Comprehensive Cancer Center), Alexei Hernandez(Sidney Kimmel Comprehensive Cancer Center)
Cited by 193
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k